Member Info for sajy

Apparently The Times will be writing an article on OPTI. As posted by Antman on X, see link below.

If true will rocket.

https://x.com/online_antz/status/1811662223049142353?s=61

Posted on X

https://x.com/mbdaytrading/status/1810958127765786830?s=61

PEW Charitable Trust raises awareness of the urgent need for new antibiotics. Destiny’s lead candidate, XF-73, is addressing this need.

https://t.co/UOc4pfnpiS

#PEW #DEST #XF73 #AMR

Great post BBN, thanks.

Main points.

Still in discussions with partners for XF73 licensing deal.

Phase 3 trial will now cost half the original amount, due to modifications. This will attract a lot mor interest now.

The cost of phase 3 trial $10M per arm. Hence looking at non dilutive funding to possibly carry out phase 3 trial on their own. What would XF73 be worth post phase 3 success.

Sebela happy to do small phase 2 trial with solid drug a then straight into phase 3 trial all funded by Sebela.

Not interested in delisting, staying on Aim.

The Rns was again poorly worded but feel much more confident after the presentation.

Did you even bother to read my post? It's not a fund raise, I am talking about the pharma partner investing in Dest as part of the licensing deal. Read my post below for more info.

I don't think it will be done at current price, don't forget discussions have been ongoing for a while now and share price was much higher. I think it could be around 40p, but would like it at 50p. At 50p that would be another 20 million shares issued to pharma and we would then be funded for several years.

Anyway all will be revealed soon.

I don’t agree, I still have faith in the management. The problem is big pharma are playing hardball over the upfront payments. CT probably wants $15 to 20 million upfront and I reckon they are only being offered bout $5 million. CT knows xf73 will be massive and is not prepared to accept such a low offer and that is why it is taking so long. I think a compromise will be reached where we get about $5 million upfront and the pharma also invests $10 million in Dest, giving Dest $15 million. These are just my thoughts.

I have shared it with a few on twitter, if your on there get in touch.

I have had a reply back from the company but won’t be posting it here as too many have a go idiots on here. If any of the genuine holders want a copy then let me know and ideally need to have an account on twitter as that would be easiest way for me to forward email.

Hi Dallo, if you don't mind can you please name the small pharma that you wanted PRTC to acquire. Thanks

We will definitely be getting an update today, confirmed by IR. Although Save has agreed to this update, I get the feeling their arm has been twisted by the regulator.

Sentiment in Dest is low with the share price on it's knees, but AMR is still a global threat as highlighted in the FT article below and in my opinion Dest has a solution in XF-73. We just need BP to sign a licensing deal and watch it rocket.

https://gsk.ft.com/article/antimicrobial-resistance?utm_source=TW&utm_medium=healthnews&utm_content=paid&twclid=2-at8sf32wbxcxi5h62b0ido39

Alamo thank you for coming here and helping us all by telling us to sell. You are a very kind person looking out for us all. Maybe you could explain why you think Dest is more likely to follow C4XD than Hemo?

Also you are saying you bought into Hemo knowing a placing was coming. This say it all about what a great investor you are. Thanks but I think I will stick with Dest.

Rumour is that we will get a Significant update on one of the 2 lead products soon. Take it with a pinch of salt as it is a rumour and I don’t if it is for XF-73 or M3.

Joanne Hart tips a few companies to purchase for the new British ISA and DEST is one of them. This is the second time she has tipped DEST as a buy.

Dest is tipped in the Mail again, see link below.

newspaper.mailplus.co.uk/data/3991/read…

"Google starts closing cookie jar for advertisers

Digital ad agencies contacted for this article wanted to know how Google ads would work when third party cookies disappeared.

They believe that Google does not really know the answer."

Btw In the trial with Renault, Silver Bullet Data Services's 4D AI solution, for advertisers, was pitted against a contextual advertising solution offered by Google (DV360).

4D AI outperformed the competitor across all metrics achieving 133% increase in clickthrough rates & 51% increase in page views.

If Google don't know the answer Silver Bullet do.

https://t.co/OBkn1yOb1u

Demise of the cookie .

https://t.co/IPYAHAjReD

Silver Bullet Data Services's, 4D IA, has just partnered with OpenX, who receive 365b billion ad requests a day.

https://t.co/xxUAidlKJb

https://twitter.com/SharePickers/status/1753153611142398372/photo/1